Former Myriad Genetics CEO Peter Durkee Meldrum Passes Away
(RTTNews.com) – Myriad Genetics Inc. ( MYGN ) said that the company’s former chief Executive officer Peter Durkee Meldrum, age 71, passed away on December 20, 2018.
Pete was a co-founder of Myriad Genetics, forming the company with Dr. Mark Skolnick in 1992. Pete steered the company from its inception through its initial public offering in 1995, to a profitable company with more than 2,500 employees that provided over two million patient test results by the time of his retirement in 2015.
“We are deeply saddened by Pete’s passing,” said Mark Capone, president and CEO, Myriad Genetics. “He was a scientific visionary and pioneer in the fields of personalized medicine and molecular diagnostics. He cared deeply about making a difference in patients’ lives by providing perfect test results which are values that we continue to live by every day.”
Pete was born on June 26, 1947, in Salt Lake City, Utah, the eldest son of Benjamin “Nibs” Meldrum and Grace Durkee Meldrum.
Read the original article on RTTNews (http://www.rttnews.com/2966012/former-myriad-genetics-ceo-peter-durkee-meldrum-passes-away.aspx)
For comments and feedback: contact editorial@rttnews.com
CRISPR 101 – Your Guide to Understanding CRISPR
Journal Club – Designer outer membrane vesicles as immunomodulatory systems – Reprogramming bacteria for vaccine delivery
Designer outer membrane vesicles as immunomodulatory systems – Reprogramming bacteria for vaccine delivery
Journal Club – Injectable nanocomposite cryogels for versatile protein drug delivery
Injectable nanocomposite cryogels for versatile protein drug delivery
Journal Club – Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy
Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy
Journal Club – Fabrication of fillable microparticles and other complex 3D microstructures
Fabrication of fillable microparticles and other complex 3D microstructures
Journal Club – Functional polyesters enable selective siRNA delivery to lung cancer over matched normal cells
Functional polyesters enable selective siRNA delivery to lung cancer over matched normal cells
Journal Club – RNAi delivery by exosome-mimetic nanovesicles – implications for targeting c-Myc in cancer
RNAi delivery by exosome-mimetic nanovesicles – implications for targeting c-Myc in cancer
Journal Club – Gas-generating TPGS-PLGA microspheres loaded with nanoparticles (NIMPS) for co-delivery of minicircle DNA and anti-tumoral drugs
Gas-generating TPGS-PLGA microspheres loaded with nanoparticles (NIMPS) for co-delivery of minicircle DNA and anti-tumoral drugs
Journal Club – Exosome-based tumor antigens-adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA
Exosome-based tumor antigens-adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA